<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">30000192</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK501133</ArticleId></ArticleIdList><Book><Publisher><PublisherName>National Institute of Child Health and Human Development</PublisherName><PublisherLocation>Bethesda (MD)</PublisherLocation></Publisher><BookTitle book="lactmed">Drugs and Lactation Database (LactMed&#xae;)</BookTitle><PubDate><Year>2006</Year></PubDate><BeginningDate><Year>2006</Year></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="lactmed" part="LM275">Valdecoxib</ArticleTitle><Language>eng</Language><PublicationType UI="D016454">Review</PublicationType><Abstract><AbstractText>Valdecoxib was removed from sale in the United States by the U.S. Food and Drug Administration because of long-term cardiovascular toxicity. Limited information indicates that levels of valdecoxib in breastmilk are low. Because there is little published experience with valdecoxib safety during breastfeeding, other agents may be preferred, especially while nursing a newborn or preterm infant.</AbstractText></Abstract><Sections><Section><SectionTitle book="lactmed" part="LM275" sec="LM275.Drug_Levels_and_Effects">Drug Levels and Effects</SectionTitle></Section><Section><SectionTitle book="lactmed" part="LM275" sec="LM275.Substance_Identification">Substance Identification</SectionTitle></Section></Sections><KeywordList Owner="NLM"><Keyword MajorTopicYN="N">Valdecoxib</Keyword><Keyword MajorTopicYN="N">Bextra</Keyword><Keyword MajorTopicYN="N">SC-65872</Keyword><Keyword MajorTopicYN="N">SC 65872</Keyword><Keyword MajorTopicYN="N">HSDB 7302</Keyword><Keyword MajorTopicYN="N">UNII-2919279Q3W</Keyword><Keyword MajorTopicYN="N">2919279Q3W</Keyword><Keyword MajorTopicYN="N">4-(5-methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide</Keyword></KeywordList><ContributionDate><Year>2024</Year><Month>9</Month><Day>15</Day></ContributionDate><ReferenceList><Reference><Citation>Hale TW. Medications in breastfeeding mothers of preterm infants. Pediatr Ann 2003;32:337-47.</Citation><ArticleIdList><ArticleId IdType="pubmed">12774709</ArticleId></ArticleIdList></Reference><Reference><Citation>Paech MJ, Salman S, Ilett KF, et al. Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: A comparison of naive pooled data analysis and nonlinear mixed-effects modeling. Anesth Analg 2012;114:837-44.</Citation><ArticleIdList><ArticleId IdType="pubmed">22344242</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho B, Chu L, Fuller A, et al. Valdecoxib for postoperative pain management after cesarean delivery: A randomized, double-blind, placebo-controlled study. Anesth Analg 2006;103:664-70.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931678</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30000192</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle></PubmedArticleSet>